Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy

Mosser, 1993, Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters, Nature, 361, 726, 10.1038/361726a0 Moser, 1999, Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls, Ann Neurol, 45, 100, 10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U Valianpour, 2003, Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry, Mol Genet Metab, 79, 189, 10.1016/S1096-7192(03)00098-2 Ferrer, 2010, General aspects and neuropathology of X-linked adrenoleukodystrophy, Brain Pathol, 20, 817, 10.1111/j.1750-3639.2010.00390.x Singh, 2010, Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis, Brain Pathol, 20, 838, 10.1111/j.1750-3639.2010.00392.x Cartier, 2009, Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy, Science, 326, 818, 10.1126/science.1171242 Mingozzi, 2011, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, Nat Rev Genet, 12, 341, 10.1038/nrg2988 Kaplitt, 2007, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, 369, 2097, 10.1016/S0140-6736(07)60982-9 Marks, 2008, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial, Lancet Neurol, 7, 400, 10.1016/S1474-4422(08)70065-6 Worgall, 2008, Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA, Hum Gene Ther, 19, 463, 10.1089/hum.2008.022 Maguire, 2009, Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial, Lancet, 374, 1597, 10.1016/S0140-6736(09)61836-5 Nathwani, 2011, Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, N Engl J Med, 365, 2357, 10.1056/NEJMoa1108046 Davidson, 2000, Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system, Proc Natl Acad Sci USA, 97, 3428, 10.1073/pnas.97.7.3428 Taymans, 2007, Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain, Hum Gene Ther, 18, 195, 10.1089/hum.2006.178 Tarantal, 2010, Long-term luciferase expression monitored by bioluminescence imaging after adeno-associated virus-mediated fetal gene delivery in rhesus monkeys (Macaca mulatta), Hum Gene Ther, 21, 143, 10.1089/hum.2009.126 Manfredsson, 2009, AAV9: a potential blood-brain barrier buster, Mol Ther, 17, 403, 10.1038/mt.2009.15 Foust, 2009, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat Biotechnol, 27, 59, 10.1038/nbt.1515 Gray, 2011, Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates, Mol Ther, 19, 1058, 10.1038/mt.2011.72 Foust, 2009, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat Biotechnol, 27, 59, 10.1038/nbt.1515 Maguire, 2008, Preventing growth of brain tumors by creating a zone of resistance, Mol Ther, 16, 1695, 10.1038/mt.2008.168 Maguire, 2012, Microvesicle-associated AAV vector as a novel gene delivery system, Mol Ther, 20, 960, 10.1038/mt.2011.303 Hubbard, 2006, Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings, Mol Genet Metab, 89, 185, 10.1016/j.ymgme.2006.05.001 Fourcade, 2008, Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy, Hum Mol Genet, 17, 1762, 10.1093/hmg/ddn085 Meijer, 2009, Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta, Cancer Gene Ther, 16, 664, 10.1038/cgt.2009.8 Yamazaki, 2014, Targeted gene transfer into ependymal cells through intraventricular injection of AAV1 vector and long-term enzyme replacement via the CSF, Sci Rep, 4, 5506, 10.1038/srep05506 Raymond, 2010, Head trauma can initiate the onset of adreno-leukodystrophy, J Neurol Sci, 290, 70, 10.1016/j.jns.2009.11.005 Musolino, 2012, Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy, Brain, 135, 2676, 10.1093/brain/aws206 Fouquet, 1997, Expression of the adrenoleukodystrophy protein in the human and mouse central nervous system, Neurobiol Dis, 3, 271, 10.1006/nbdi.1997.0127 Höftberger, 2007, Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy, Neurobiol Dis, 28, 165, 10.1016/j.nbd.2007.07.007 Baarine, 2012, Evidence of oxidative stress in very long chain fatty acid–treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins, Neuroscience, 213, 1, 10.1016/j.neuroscience.2012.03.058 Eichler, 2008, Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?, Ann Neurol, 63, 729, 10.1002/ana.21391 Dirren, 2014, Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord, Hum Gene Ther, 25, 109, 10.1089/hum.2013.021 von Jonquieres, 2013, Glial promoter selectivity following AAV-delivery to the immature brain, PLoS ONE, 8, e65646, 10.1371/journal.pone.0065646 Murphy, 2013, Acat1 knockdown gene therapy decreases amyloid-ß in a mouse model of Alzheimer's disease, Mol Ther, 21, 1497, 10.1038/mt.2013.118 Quattrocelli, 2013, Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice, J Am Heart Assoc, 2, e000284, 10.1161/JAHA.113.000284 Singh, 1981, Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex, Biochem Biophys Res Commun, 102, 1223, 10.1016/S0006-291X(81)80142-8 Moser, 1981, Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids, Neurology, 31, 1241, 10.1212/WNL.31.10.1241 Forss-Petter, 1997, Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice, J Neurosci Res, 50, 829, 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W Samaranch, 2013, Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates, Hum Gene Ther, 24, 526, 10.1089/hum.2013.005 Foust, 2013, Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS, Mol Ther, 21, 2148, 10.1038/mt.2013.211 Murrey, 2014, Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates, Hum Gene Ther Clin Dev, 25, 72, 10.1089/humc.2013.208 Samaranch, 2012, Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates, Hum Gene Ther, 23, 382, 10.1089/hum.2011.200 Bevan, 2011, Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders, Mol Ther, 19, 1971, 10.1038/mt.2011.157 Gray, 2013, Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates, Gene Ther, 20, 450, 10.1038/gt.2012.101 Mattar, 2013, Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems, Gene Ther, 20, 69, 10.1038/gt.2011.216